(MedPage Today) -- SILVER SPRING, Md. -- A recombinant fusion drug combining the Factor VIII protein with a peptide to extend its lifetime in circulation has been approved for treating hemophilia A, the FDA said. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment